These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 2757966)

  • 1. Factor IX Kawachinagano: impaired function of the Gla-domain caused by attached propeptide region due to substitution of arginine by glutamine at position -4.
    Sugimoto M; Miyata T; Kawabata S; Yoshioka A; Fukui H; Iwanaga S
    Br J Haematol; 1989 Jun; 72(2):216-21. PubMed ID: 2757966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Arg-4 mutant factor IX Strasbourg 2 shows a delayed activation by factor XIa.
    de la Salle C; Charmantier JL; Ravanat C; Ohlmann P; Hartmann ML; Schuhler S; Bischoff R; Ebel C; Roecklin D; Balland A
    Nouv Rev Fr Hematol (1978); 1993; 35(5):473-80. PubMed ID: 8295821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood clotting factor IX Kashihara: amino acid substitution of valine-182 by phenylalanine.
    Sakai T; Yoshioka A; Yamamoto K; Niinomi K; Fujimura Y; Fukui H; Miyata T; Iwanaga S
    J Biochem; 1989 May; 105(5):756-9. PubMed ID: 2753873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factor IX San Dimas. Substitution of glutamine for Arg-4 in the propeptide leads to incomplete gamma-carboxylation and altered phospholipid binding properties.
    Ware J; Diuguid DL; Liebman HA; Rabiet MJ; Kasper CK; Furie BC; Furie B; Stafford DW
    J Biol Chem; 1989 Jul; 264(19):11401-6. PubMed ID: 2738071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modification of the N-terminus of human factor IX by defective propeptide cleavage or acetylation results in a destabilized calcium-induced conformation: effects on phospholipid binding and activation by factor XIa.
    Wojcik EG; Van Den Berg M; Poort SR; Bertina RM
    Biochem J; 1997 May; 323 ( Pt 3)(Pt 3):629-36. PubMed ID: 9169594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood clotting factor IX Niigata: substitution of alanine-390 by valine in the catalytic domain.
    Sugimoto M; Miyata T; Kawabata S; Yoshioka A; Fukui H; Takahashi H; Iwanaga S
    J Biochem; 1988 Dec; 104(6):878-80. PubMed ID: 3243764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneity of factor IX BM. Difference of cleavage sites by factor XIa and Ca2+ in factor IX Kashihara, factor IX Nagoya and factor IX Niigata.
    Yoshioka A; Ohkubo Y; Nishimura T; Tanaka I; Fukui H; Ogata K; Kamiya T; Takahashi H
    Thromb Res; 1986 Jun; 42(5):595-604. PubMed ID: 3487139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Membrane binding properties of the factor IX gamma-carboxyglutamic acid-rich domain prepared by chemical synthesis.
    Jacobs M; Freedman SJ; Furie BC; Furie B
    J Biol Chem; 1994 Oct; 269(41):25494-501. PubMed ID: 7929250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factor IX Fukuoka. Substitution of ASN92 by His in the second epidermal growth factor-like domain results in defective interaction with factors VIIa/X.
    Nishimura H; Takeya H; Miyata T; Suehiro K; Okamura T; Niho Y; Iwanaga S
    J Biol Chem; 1993 Nov; 268(32):24041-6. PubMed ID: 8226948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defective propeptide processing and abnormal activation underlie the molecular pathology of factor IX Troed-y-Rhiw.
    Liddell MB; Lillicrap DP; Peake IR; Bloom AL
    Br J Haematol; 1989 Jun; 72(2):208-15. PubMed ID: 2788012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defective propeptide processing of blood clotting factor IX caused by mutation of arginine to glutamine at position -4.
    Bentley AK; Rees DJ; Rizza C; Brownlee GG
    Cell; 1986 May; 45(3):343-8. PubMed ID: 3009023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the defect in activation of factor IX Chapel Hill by human factor XIa.
    Braunstein KM; Noyes CM; Griffith MJ; Lundblad RL; Roberts HR
    J Clin Invest; 1981 Dec; 68(6):1420-6. PubMed ID: 6976355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of the molecular defect in factor IX Chapel Hill: substitution of histidine for arginine at position 145.
    Noyes CM; Griffith MJ; Roberts HR; Lundblad RL
    Proc Natl Acad Sci U S A; 1983 Jul; 80(14):4200-2. PubMed ID: 6603618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the propeptide and gamma-glutamic acid domain of factor IX for in vitro carboxylation by the vitamin K-dependent carboxylase.
    Stanley TB; Wu SM; Houben RJ; Mutucumarana VP; Stafford DW
    Biochemistry; 1998 Sep; 37(38):13262-8. PubMed ID: 9748333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The propeptide region of clotting factor IX is a signal for a vitamin K dependent carboxylase: evidence from protein engineering of amino acid -4.
    Galeffi P; Brownlee GG
    Nucleic Acids Res; 1987 Nov; 15(22):9505-13. PubMed ID: 3684602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First epidermal growth factor-like domain of human blood coagulation factor IX is required for its activation by factor VIIa/tissue factor but not by factor XIa.
    Zhong D; Smith KJ; Birktoft JJ; Bajaj SP
    Proc Natl Acad Sci U S A; 1994 Apr; 91(9):3574-8. PubMed ID: 8170949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood clotting factor IX Nagoya 3: the molecular defect of zymogen activation caused by an arginine-145 to histidine substitution.
    Suehiro K; Miyata T; Takeya H; Takamatsu J; Saito H; Murakawa M; Okamura T; Niho Y; Iwanaga S
    Thromb Res; 1990 Nov; 60(4):311-20. PubMed ID: 2087690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. gamma-Carboxyglutamic acids 36 and 40 do not contribute to human factor IX function.
    Gillis S; Furie BC; Furie B; Patel H; Huberty MC; Switzer M; Foster WB; Scoble HA; Bond MD
    Protein Sci; 1997 Jan; 6(1):185-96. PubMed ID: 9007991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factor IX Zutphen: a Cys18-->Arg mutation results in formation of a heterodimer with alpha 1-microglobulin and the inability to form a calcium-induced conformation.
    Wojcik EG; van den Berg M; van der Linden IK; Poort SR; Cupers R; Bertina RM
    Biochem J; 1995 Nov; 311 ( Pt 3)(Pt 3):753-9. PubMed ID: 7487929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The factor IX gamma-carboxyglutamic acid (Gla) domain is involved in interactions between factor IX and factor XIa.
    Aktimur A; Gabriel MA; Gailani D; Toomey JR
    J Biol Chem; 2003 Mar; 278(10):7981-7. PubMed ID: 12496253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.